Find Tofacitinib Citrate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

MARKET PLACE

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 540737-29-9, Tasocitinib citrate, Xeljanz, Cp-690550 citrate, Tofacitinib (citrate), Tofacitinib (cp-690550) citrate
Molecular Formula
C22H28N6O8
Molecular Weight
504.5  g/mol
InChI Key
SYIKUFDOYJFGBQ-YLAFAASESA-N
FDA UNII
O1FF4DIV0D

Tofacitinib Citrate
1 2D Structure

Tofacitinib Citrate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-hydroxypropane-1,2,3-tricarboxylic acid;3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile
2.1.2 InChI
InChI=1S/C16H20N6O.C6H8O7/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16;7-3(8)1-6(13,5(11)12)2-4(9)10/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t11-,13+;/m1./s1
2.1.3 InChI Key
SYIKUFDOYJFGBQ-YLAFAASESA-N
2.1.4 Canonical SMILES
CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
2.1.5 Isomeric SMILES
C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
2.2 Other Identifiers
2.2.1 UNII
O1FF4DIV0D
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Cp 690,550

2. Cp 690550

3. Cp-690,550

4. Cp-690550

5. Cp690550

6. Tasocitinib

7. Tofacitinib

8. Xeljanz

2.3.2 Depositor-Supplied Synonyms

1. 540737-29-9

2. Tasocitinib Citrate

3. Xeljanz

4. Cp-690550 Citrate

5. Tofacitinib (citrate)

6. Tofacitinib (cp-690550) Citrate

7. Xeljanz Xr

8. Tofacitinib Citrate [usan]

9. Cp-690,550-10

10. Tasocitinib Monocitrate

11. 540737-29-9 (citrate)

12. Cp-690550-10

13. Cp 690550 Citrate

14. O1ff4div0d

15. 3-((3r,4r)-4-methyl-3-(methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate

16. Chebi:71197

17. 1-piperidinepropanenitrile, 4-methyl-3-(methyl-7h-pyrrolo(2,3-d)pyrimidin-4-ylamino)- Beta-oxo-, (3r,4r)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)

18. 2-hydroxypropane-1,2,3-tricarboxylic Acid; 3-[(3r,4r)-4-methyl-3-[methyl({7h-pyrrolo[2,3-d]pyrimidin-4-yl})amino]piperidin-1-yl]-3-oxopropanenitrile

19. 2-hydroxypropane-1,2,3-tricarboxylic Acid;3-[(3r,4r)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile

20. Unii-o1ff4div0d

21. Mfcd11616529

22. 3-{(3r,4r)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate

23. 3-{(3r,4r)-4-methyl-3-[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile Citrate Salt

24. 3-{(3r,4r)-4-methyl-3-[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl}-amino]-piperidin-1-yl)-3-oxo-propionitrile Citrate Salt

25. Xeljanz (tn)

26. Tofacitinib Monocitrate

27. Tasocitinib Citric Acid Salt

28. Cep-18770(delanzomib)

29. Mls006010058

30. Schembl1374185

31. Chembl2103743

32. Tofacitinib Citrate (jan/usan)

33. Amy4175

34. Dtxsid80202404

35. Ex-a204

36. Tofacitinib Citrate [jan]

37. C16h20n6o.c6h8o7

38. Tofacitinib Monocitrate [mi]

39. Hy-40354a

40. S5001

41. Tofacitinib Citrate [who-dd]

42. Akos022178222

43. Cp-690550 - Tofacitinib Citrate

44. Tofacitinib Citrate, >=98% (hplc)

45. Ccg-269730

46. Cs-0928

47. Tofacitinib Citrate [orange Book]

48. Ac-25004

49. As-19392

50. Bt163661

51. Smr004701220

52. Cp-690550 Citrate (tofacitinib Citrate)

53. Tofacitinib Citrate (cp-690550 Citrate)

54. Cp 690550-10

55. D09783

56. Q27139435

57. (3r,4r)-4-methyl-3-(methyl-7h-pyrro Lo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepro Panenitrile Citrate

58. (3r,4r)-4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-?-oxo-1-piperidinepropanenitrile Citrate

59. (3r,4r)-4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidine Propanenitrile 2-hydroxy-1,2,3-propanetricarboxylate

60. (3r,4r)-4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-ss-oxo-1-piperidinepropanenitrile Citrate Salt

61. 1-piperidinepropanenitrile, 4-methyl-3-(methyl-7h-pyrrolo(2,3-d)pyrimidin-4-ylamino)-.beta.-oxo-, (3r,4r)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)

62. 1-piperidinepropanenitrile,4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-,(3r,4r)-,2-hydroxy-1,2,3-propanetricarboxylate(1:1)

63. 3-((3r,4r)-4-methyl-3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxo-propanenitrile2-hydroxypropane-1,2,3-tricarboxylate (1:1)

64. 3-((3r,4r)-4-methyl-3-(methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile Mono Citrate Salt

65. 3-{(3r,4r)-4-methyl-3-[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile Mono Citrate Salt

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 504.5 g/mol
Molecular Formula C22H28N6O8
Hydrogen Bond Donor Count5
Hydrogen Bond Acceptor Count12
Rotatable Bond Count8
Exact Mass504.19686187 g/mol
Monoisotopic Mass504.19686187 g/mol
Topological Polar Surface Area221 Ų
Heavy Atom Count36
Formal Charge0
Complexity716
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameXeljanz
PubMed HealthTofacitinib (By mouth)
Drug ClassesAntirheumatic, Musculoskeletal Agent
Drug LabelXELJANZ is the citrate salt of tofacitinib, a JAK inhibitor.Tofacitinib citrate is a white to off-white powder with the following chemical name: (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo [2,3-d]pyrimidin-4-ylamino)--oxo-1-piperidinepropanenitrile, 2-hy...
Active IngredientTofacitinib citrate
Dosage FormTablet
RouteOral
Strengtheq 5mg base
Market StatusPrescription
CompanyPf Prism Cv

2 of 2  
Drug NameXeljanz
PubMed HealthTofacitinib (By mouth)
Drug ClassesAntirheumatic, Musculoskeletal Agent
Drug LabelXELJANZ is the citrate salt of tofacitinib, a JAK inhibitor.Tofacitinib citrate is a white to off-white powder with the following chemical name: (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo [2,3-d]pyrimidin-4-ylamino)--oxo-1-piperidinepropanenitrile, 2-hy...
Active IngredientTofacitinib citrate
Dosage FormTablet
RouteOral
Strengtheq 5mg base
Market StatusPrescription
CompanyPf Prism Cv

5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Janus Kinase Inhibitors

Agents that inhibit JANUS KINASES. (See all compounds classified as Janus Kinase Inhibitors.)


API SUPPLIERS

read-more
read-more

01

Minakem

France

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMinakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

Flag France
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Minakem Comapny Banner

02

Minakem (formerly Delmar Chemicals...

Canada

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMinakem is manufacturing small molecules APIs including corticosteroids

Flag Canada
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
Minakem Delmar

03

LGM Pharma

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
LGM Pharma CB

04

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WCarrow-down NDC arrow-down KDMF VMF Others AUDIT arrow-down
Metrochem

05

Dr. Reddy's Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WCInactive-api NDC arrow-down KDMF VMF Others AUDIT arrow-down
Dr Reddy Company Banner

06

Aarti Pharmalabs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Aarti Industries Company Banner

07

Shanghai Minbiotech

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Shanghai Minbiotech CB

08

Tagoor Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Tagoor Laboratories

09

Tenatra Exports

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Tenatra

10

Chunghwa Chemical Synthesis & Biot...

Taiwan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.

Flag Taiwan
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
CCSB Company Banner
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMinakem is manufacturing small molecules APIs including corticosteroids

Flag Canada
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 33332

Submission : 2018-12-21

Status : Active

Type : II

Minakem Delmar

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 35976

Submission : 2021-05-29

Status : Active

Type : II

Metrochem

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2024-03-06

Pay. Date : 2024-01-31

DMF Number : 38994

Submission : 2023-12-02

Status : Active

Type : II

Metrochem

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2023-12-20

Pay. Date : 2023-11-15

DMF Number : 37164

Submission : 2022-07-29

Status : Active

Type : II

Dr Reddy Company Banner

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.

Flag Taiwan
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 37532

Submission : 2022-10-28

Status : Active

Type : II

CCSB Company Banner

06

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHonour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2022-06-22

Pay. Date : 2022-05-04

DMF Number : 36542

Submission : 2022-06-03

Status : Active

Type : II

Company Banner

07

PEGS Boston Summit
Not Confirmed

07

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2015-05-08

Pay. Date : 2015-03-10

DMF Number : 29002

Submission : 2015-03-11

Status : Active

Type : II

blank

08

PEGS Boston Summit
Not Confirmed

08

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2015-11-13

Pay. Date : 2015-09-23

DMF Number : 27721

Submission : 2013-11-30

Status : Active

Type : II

blank

09

PEGS Boston Summit
Not Confirmed

09

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2016-10-21

Pay. Date : 2016-06-22

DMF Number : 30578

Submission : 2016-06-13

Status : Active

Type : II

blank

10

Sintenovo Sa De Cv

Mexico

USDMF

arrow
PEGS Boston Summit
Not Confirmed

10

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 30554

Submission : 2016-05-19

Status : Inactive

Type : II

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Methotrexate is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Rheumatic Diseases.


Lead Product(s): Methotrexate,Sulfasalazine,Hydroxychloroquine Sulphate,Leflunomide,Azathioprine,Mycophenolic Acid,Cyclosporine,Tacrolimus,

Therapeutic Area: Rheumatology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Cytotoxic Drug

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 24, 2025

blank

01

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Methotrexate is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Rheumatic Diseases.

Product Name : Undisclosed

Product Type : Cytotoxic Drug

Upfront Cash : Inapplicable

August 24, 2025

blank
  • Development Update

Details:

Tofacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.


Lead Product(s): Tofacitinib Citrate,CGB-500

Therapeutic Area: Dermatology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 11, 2025

blank

02

CAGE Bio

Country
arrow
PEGS Boston Summit
Not Confirmed

CAGE Bio

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Tofacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 11, 2025

blank
  • Development Update

Details:

Tofacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.


Lead Product(s): Tofacitinib Citrate,CGB-500

Therapeutic Area: Dermatology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 05, 2025

blank

03

CAGE Bio

Country
arrow
PEGS Boston Summit
Not Confirmed

CAGE Bio

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Tofacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 05, 2025

blank

Details:

The net proceeds will be used to fund the clinical development of its oral biotherapeutics platform, BT-600 (tofacitinib) for the treatment of Ulcerative Colitis.


Lead Product(s): Tofacitinib Citrate,Inapplicable

Therapeutic Area: Immunology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: H.C. Wainwright & Co

Deal Size: $3.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering October 29, 2024

blank

04

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Lead Product(s) : Tofacitinib Citrate,Inapplicable

Therapeutic Area : Immunology

Highest Development Status : Phase I

Partner/Sponsor/Collaborator : H.C. Wainwright & Co

Deal Size : $3.0 million

Deal Type : Public Offering

Details : The net proceeds will be used to fund the clinical development of its oral biotherapeutics platform, BT-600 (tofacitinib) for the treatment of Ulcerative Colitis.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Undisclosed

October 29, 2024

blank

Details:

BT-600 (tofacitinib) is a drug-device combination program consisting of the orally administered NaviCap™ device which delivers tofacitinib to the colon for treatment of ulcerative colitis.


Lead Product(s): Tofacitinib Citrate,Inapplicable

Therapeutic Area: Immunology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 18, 2024

blank

05

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : BT-600 (tofacitinib) is a drug-device combination program consisting of the orally administered NaviCap™ device which delivers tofacitinib to the colon for treatment of ulcerative colitis.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

July 18, 2024

blank

Details:

BT-600 (tofacitinib) is a drug-device combination program consisting of the orally administered NaviCap™ device which delivers tofacitinib to the colon for treatment of ulcerative colitis.


Lead Product(s): Tofacitinib Citrate,Inapplicable

Therapeutic Area: Immunology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 01, 2024

blank

06

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : BT-600 (tofacitinib) is a drug-device combination program consisting of the orally administered NaviCap™ device which delivers tofacitinib to the colon for treatment of ulcerative colitis.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

July 01, 2024

blank

Details:

BT-600 (tofacitinib) is a drug-device combination using the NaviCap™ device to deliver a liquid formulation of tofacitinib to the colon, aimed at treating moderate to severe ulcerative colitis.


Lead Product(s): Tofacitinib Citrate,Inapplicable

Therapeutic Area: Immunology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 30, 2024

blank

07

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : BT-600 (tofacitinib) is a drug-device combination using the NaviCap™ device to deliver a liquid formulation of tofacitinib to the colon, aimed at treating moderate to severe ulcerative colitis.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 30, 2024

blank

Details:

BT-600 is a drug device combination containing liquid formulation of tofacitinib (JAK inhibitor). It is being evaluated for the treatment of ulcerative colitis


Lead Product(s): Tofacitinib Citrate,Inapplicable

Therapeutic Area: Immunology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 04, 2024

blank

08

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : BT-600 is a drug device combination containing liquid formulation of tofacitinib (JAK inhibitor). It is being evaluated for the treatment of ulcerative colitis

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 04, 2024

blank

Details:

Biora intends to use the net proceeds from this offering to support its operations, complete its ongoing BT-600 (tofacitinib) clinical trial for the treatment of moderate to severe ulcerative colitis.


Lead Product(s): Tofacitinib Citrate,Inapplicable

Therapeutic Area: Immunology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: H.C. Wainwright & Co

Deal Size: $6.0 million Upfront Cash: Undisclosed

Deal Type: Private Placement April 03, 2024

blank

09

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Lead Product(s) : Tofacitinib Citrate,Inapplicable

Therapeutic Area : Immunology

Highest Development Status : Phase I

Partner/Sponsor/Collaborator : H.C. Wainwright & Co

Deal Size : $6.0 million

Deal Type : Private Placement

Details : Biora intends to use the net proceeds from this offering to support its operations, complete its ongoing BT-600 (tofacitinib) clinical trial for the treatment of moderate to severe ulcerative colitis.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Undisclosed

April 03, 2024

blank

Details:

Biora intends to complete its clinical trial of BT-600, a drug-device combination delivering tofacitinib to the colon for treating moderate to severe ulcerative colitis.


Lead Product(s): Tofacitinib Citrate,Inapplicable

Therapeutic Area: Immunology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: H.C. Wainwright & Co

Deal Size: $6.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering April 01, 2024

blank

10

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Lead Product(s) : Tofacitinib Citrate,Inapplicable

Therapeutic Area : Immunology

Highest Development Status : Phase I

Partner/Sponsor/Collaborator : H.C. Wainwright & Co

Deal Size : $6.0 million

Deal Type : Public Offering

Details : Biora intends to complete its clinical trial of BT-600, a drug-device combination delivering tofacitinib to the colon for treating moderate to severe ulcerative colitis.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Undisclosed

April 01, 2024

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATE SUPPLIERS

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothZhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.

CAS Number : 3680-69-1

End Use API : Tofacitinib Citrate

About The Company : Established in 2004 and headquartered in Hangzhou, Hengkang established multiple factories, research and sales centers in Zhejiang, Shandong, and Henan. With fa...

Zhejiang Hengkang Pharmaceutical

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothZhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.

CAS Number : 1062580-52-2

End Use API : Tofacitinib Citrate

About The Company : Established in 2004 and headquartered in Hangzhou, Hengkang established multiple factories, research and sales centers in Zhejiang, Shandong, and Henan. With fa...

Zhejiang Hengkang Pharmaceutical

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

CAS Number : 3680-69-1

End Use API : Tofacitinib Citrate

About The Company : Aarti Pharmalabs is generic APIs & Intermediates manufacturing company & small molecule drug substance CDMO and the largest Indian manufacturer of Xanthine Deri...

Aarti Industries Company Banner

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

CAS Number : 1062580-52-2

End Use API : Tofacitinib Citrate

About The Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square mete...

Shanghai Minbiotech CB

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

CAS Number : 479633-63-1

End Use API : Tofacitinib Citrate

About The Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square mete...

Shanghai Minbiotech CB

06

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.

CAS Number : 1062580-52-2

End Use API : Tofacitinib Citrate

About The Company : Tagoor Laboratories, established in 2018 and part of the Tagoor Group, provides APIs, advanced intermediates, and key starting materials for critical and high-g...

Tagoor Laboratories

07

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothIndian Drugs & Chemicals – delivering trusted APIs, intermediates & fine chemicals worldwide with 40+ years of quality expertise.

CAS Number : 84905-80-6

End Use API : Tofacitinib Citrate

About The Company : Indian Drugs And Chemicals supplies quality products using modern technologies, supported by strong industry expertise. The company serves global markets with a...

Company Banner

08

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 3680-69-1

End Use API : Tofacitinib Citrate

About The Company : Allsino Pharmaceutical, established in May 2004, spans 97,350m² and specializes in the R&D and manufacturing of RSMs, GMP intermediates, and APIs. Our products...

blank

09

Almelo

India
PEGS Boston Summit
Not Confirmed
arrow

Almelo

India
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : CAS-477600-74-1

End Use API : Tofacitinib Citrate

About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...

blank

10

Almelo

India
PEGS Boston Summit
Not Confirmed
arrow

Almelo

India
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : CAS-477600-70-7

End Use API : Tofacitinib Citrate

About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

Regulatory Info :

Registration Country : India

Tofacitinib

Brand Name : Tofacitinib XR

Dosage Form : Oral

Dosage Strength : 22 mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

Dr Reddy Company Banner

02

TOFACITINIB

Brand Name : TOFACITINIB

Dosage Form : TABLET;ORAL

Dosage Strength : 5MG

Packaging :

Approval Date :

Application Number : 209633

Regulatory Info :

Registration Country : USA

Breckenridge Pharmaceutical

03

NanoAlvand

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

Flag Iran
Digital Content Digital Content

Regulatory Info :

Registration Country : Iran

Tofacitinib Citrate

Brand Name : Rhofanib

Dosage Form : Film Coated Tablet

Dosage Strength : 5MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Iran

NanoAlvand

04

NanoAlvand

Iran
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.

Flag Iran
Digital Content Digital Content

Regulatory Info :

Registration Country : Iran

Tofacitinib Citrate

Brand Name : Rhofanib

Dosage Form : Film Coated Tablet

Dosage Strength : 10MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Iran

NanoAlvand

05

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

TOFACITINIB CITRATE

Brand Name : TOFACITINIB CITRATE

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 5MG BASE

Packaging :

Approval Date : 2023-03-13

Application Number : 209738

Regulatory Info : DISCN

Registration Country : USA

blank

06

Pfizer Inc

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

Pfizer Inc

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

TOFACITINIB CITRATE

Brand Name : XELJANZ

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 5MG BASE

Packaging :

Approval Date : 2012-11-06

Application Number : 203214

Regulatory Info : RX

Registration Country : USA

blank

07

Pfizer Inc

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

Pfizer Inc

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

TOFACITINIB CITRATE

Brand Name : XELJANZ

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 10MG BASE

Packaging :

Approval Date : 2018-05-30

Application Number : 203214

Regulatory Info : RX

Registration Country : USA

blank

08

Pfizer Inc

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

Pfizer Inc

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

TOFACITINIB CITRATE

Brand Name : XELJANZ XR

Dosage Form : TABLET, EXTENDED RELEASE;ORAL

Dosage Strength : EQ 11MG BASE

Packaging :

Approval Date : 2016-02-23

Application Number : 208246

Regulatory Info : RX

Registration Country : USA

blank

09

Pfizer Inc

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

Pfizer Inc

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

TOFACITINIB CITRATE

Brand Name : XELJANZ XR

Dosage Form : TABLET, EXTENDED RELEASE;ORAL

Dosage Strength : EQ 22MG BASE

Packaging :

Approval Date : 2019-12-12

Application Number : 208246

Regulatory Info : RX

Registration Country : USA

blank

10

Prinston

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

Prinston

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

TOFACITINIB

Brand Name : TOFACITINIB

Dosage Form : TABLET;ORAL

Dosage Strength : 5MG

Packaging :

Approval Date :

Application Number : 209923

Regulatory Info :

Registration Country : USA

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

02

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

TOFACITINIB

Brand Name : TOFACITINIB

Dosage Form : TABLET

Dosage Strength : 5MG

Approval Date :

Application Number : 218437

RX/OTC/DISCN :

RLD :

TE Code :

blank

03

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

TOFACITINIB

Brand Name : TOFACITINIB

Dosage Form : TABLET

Dosage Strength : 5MG

Approval Date :

Application Number : 215356

RX/OTC/DISCN :

RLD :

TE Code :

blank

04

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

TOFACITINIB CITRATE

Brand Name : TOFACITINIB CITRATE

Dosage Form : TABLET, EXTENDED RELEASE;ORAL

Dosage Strength : EQ 11MG BASE

Approval Date : 2024-06-03

Application Number : 218462

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank

05

DEXCEL

Israel
PEGS Boston Summit
Not Confirmed
arrow

DEXCEL

Israel
arrow
PEGS Boston Summit
Not Confirmed

TOFACITINIB CITRATE

Brand Name : TOFACITINIB CITRATE

Dosage Form : TABLET, EXTENDED RELEASE;ORAL

Dosage Strength : EQ 11MG BASE

Approval Date : 2024-12-16

Application Number : 218668

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank

06

PF PRISM CV

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

PF PRISM CV

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

TOFACITINIB CITRATE

Brand Name : XELJANZ

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 5MG BASE

Approval Date : 2012-11-06

Application Number : 203214

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

07

PF PRISM CV

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

PF PRISM CV

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

TOFACITINIB CITRATE

Brand Name : XELJANZ

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 10MG BASE

Approval Date : 2018-05-30

Application Number : 203214

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

08

PFIZER

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

PFIZER

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

TOFACITINIB CITRATE

Brand Name : XELJANZ XR

Dosage Form : TABLET, EXTENDED RELEASE;ORAL

Dosage Strength : EQ 11MG BASE

Approval Date : 2016-02-23

Application Number : 208246

RX/OTC/DISCN : RX

RLD : Yes

TE Code : AB

blank

09

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Tofacitinib

Brand Name : Tofacitinib

Dosage Form : TABLET;ORAL

Dosage Strength : 5MG

Approval Date :

Application Number : 215552

RX/OTC/DISCN :

RLD :

TE Code :

blank

10

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Tofacitinib

Brand Name : Tofacitinib

Dosage Form : TABLET;ORAL

Dosage Strength : 10MG

Approval Date :

Application Number : 215552

RX/OTC/DISCN :

RLD :

TE Code :

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Direct Compression

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Granulation

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Lubricants & Glidants

read-more
read-more

Co-Processed Excipients

read-more
read-more

Coating Systems & Additives

read-more
read-more

Taste Masking

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Solubilizers

read-more
read-more

Controlled & Modified Release

read-more
read-more

Parenteral

read-more
read-more

Topical

read-more
read-more

Emulsifying Agents

read-more
read-more

Rheology Modifiers

read-more
read-more

Soft Gelatin

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Annual Reports

read-more
read-more

01

Brand Name : Xeljanz

Tofacitinib Citrate

arrow
PEGS Boston Summit
Not Confirmed

Brand Name : Xeljanz

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Tofacitinib Citrate

Main Therapeutic Indication : Immunology

Currency : USD

2019 Revenue in Millions : 2,242

2018 Revenue in Millions : 1,774

Growth (%) : 26

blank

02

Brand Name : Xeljanz

Tofacitinib Citrate

arrow
PEGS Boston Summit
Not Confirmed

Brand Name : Xeljanz

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Tofacitinib Citrate

Main Therapeutic Indication : Immunology

Currency : USD

2020 Revenue in Millions : 2,437

2019 Revenue in Millions : 2,242

Growth (%) : 9

blank

03

Brand Name : Xeljanz

Tofacitinib Citrate

arrow
PEGS Boston Summit
Not Confirmed

Brand Name : Xeljanz

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Tofacitinib Citrate

Main Therapeutic Indication : Immunology

Currency : USD

2021 Revenue in Millions : 2,455

2020 Revenue in Millions : 2,437

Growth (%) : 1

blank

04

Brand Name : Xeljanz

Tofacitinib Citrate

arrow
PEGS Boston Summit
Not Confirmed

Brand Name : Xeljanz

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Tofacitinib Citrate

Main Therapeutic Indication : Immunology

Currency : USD

2022 Revenue in Millions : 1,796

2021 Revenue in Millions : 2,455

Growth (%) : -27

blank

05

Brand Name : Xeljanz

Tofacitinib Citrate

arrow
PEGS Boston Summit
Not Confirmed

Brand Name : Xeljanz

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Tofacitinib Citrate

Main Therapeutic Indication : Immunology

Currency : USD

2023 Revenue in Millions : 1,703

2022 Revenue in Millions : 1,796

Growth (%) : -5

blank

06

Brand Name : Xeljanz

Tofacitinib Citrate

arrow
PEGS Boston Summit
Not Confirmed

Brand Name : Xeljanz

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Tofacitinib Citrate

Main Therapeutic Indication : Immunology

Currency : USD

2024 Revenue in Millions : 1,168

2023 Revenue in Millions : 1,703

Growth (%) : -31

blank

07

Brand Name : Xeljanz

Tofacitinib Citrate

arrow
PEGS Boston Summit
Not Confirmed

Brand Name : Xeljanz

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Tofacitinib Citrate

Main Therapeutic Indication : Immunology (Organ Transplant, Arthr...

Currency : USD

2015 Revenue in Millions : 308

2014 Revenue in Millions : 523

Growth (%) : 70%

blank

08

Brand Name : Xeljianz

Tofacitinib Citrate

arrow
PEGS Boston Summit
Not Confirmed

Brand Name : Xeljianz

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Tofacitinib Citrate

Main Therapeutic Indication : Immunology (Organ Transplant, Arthr...

Currency : USD

2014 Revenue in Millions : 170.20%

2013 Revenue in Millions :

Growth (%) :

blank

09

Brand Name : Xeljanz

Tofacitinib Citrate

arrow
PEGS Boston Summit
Not Confirmed

Brand Name : Xeljanz

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Tofacitinib Citrate

Main Therapeutic Indication : Immunology (Organ Transplant, Arthr...

Currency : USD

2016 Revenue in Millions : 927

2015 Revenue in Millions : 524

Growth (%) : 77

blank

10

Brand Name : Xeljanz

Tofacitinib Citrate

arrow
PEGS Boston Summit
Not Confirmed

Brand Name : Xeljanz

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Tofacitinib Citrate

Main Therapeutic Indication : Immunology (Organ Transplant, Arthr...

Currency : USD

2017 Revenue in Millions : 1,345

2016 Revenue in Millions : 927

Growth (%) : 45

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

APIs

read-more
read-more
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Looking for 540737-29-9 / Tofacitinib Citrate API manufacturers, exporters & distributors?

Tofacitinib Citrate manufacturers, exporters & distributors 1

67

PharmaCompass offers a list of Tofacitinib Citrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Tofacitinib Citrate manufacturer or Tofacitinib Citrate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Tofacitinib Citrate manufacturer or Tofacitinib Citrate supplier.

API | Excipient name

Tofacitinib Citrate

Synonyms

540737-29-9, Tasocitinib citrate, Xeljanz, Cp-690550 citrate, Tofacitinib (citrate), Tofacitinib (cp-690550) citrate

Cas Number

540737-29-9

Unique Ingredient Identifier (UNII)

O1FF4DIV0D

Tofacitinib Manufacturers

A Tofacitinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tofacitinib, including repackagers and relabelers. The FDA regulates Tofacitinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tofacitinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Tofacitinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Tofacitinib Suppliers

A Tofacitinib supplier is an individual or a company that provides Tofacitinib active pharmaceutical ingredient (API) or Tofacitinib finished formulations upon request. The Tofacitinib suppliers may include Tofacitinib API manufacturers, exporters, distributors and traders.

click here to find a list of Tofacitinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Tofacitinib USDMF

A Tofacitinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Tofacitinib active pharmaceutical ingredient (API) in detail. Different forms of Tofacitinib DMFs exist exist since differing nations have different regulations, such as Tofacitinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Tofacitinib DMF submitted to regulatory agencies in the US is known as a USDMF. Tofacitinib USDMF includes data on Tofacitinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tofacitinib USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Tofacitinib suppliers with USDMF on PharmaCompass.

Tofacitinib JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Tofacitinib Drug Master File in Japan (Tofacitinib JDMF) empowers Tofacitinib API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Tofacitinib JDMF during the approval evaluation for pharmaceutical products. At the time of Tofacitinib JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Tofacitinib suppliers with JDMF on PharmaCompass.

Tofacitinib KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Tofacitinib Drug Master File in Korea (Tofacitinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Tofacitinib. The MFDS reviews the Tofacitinib KDMF as part of the drug registration process and uses the information provided in the Tofacitinib KDMF to evaluate the safety and efficacy of the drug.

After submitting a Tofacitinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Tofacitinib API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Tofacitinib suppliers with KDMF on PharmaCompass.

Tofacitinib WC

A Tofacitinib written confirmation (Tofacitinib WC) is an official document issued by a regulatory agency to a Tofacitinib manufacturer, verifying that the manufacturing facility of a Tofacitinib active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Tofacitinib APIs or Tofacitinib finished pharmaceutical products to another nation, regulatory agencies frequently require a Tofacitinib WC (written confirmation) as part of the regulatory process.

click here to find a list of Tofacitinib suppliers with Written Confirmation (WC) on PharmaCompass.

Tofacitinib NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tofacitinib as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Tofacitinib API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Tofacitinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Tofacitinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tofacitinib NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Tofacitinib suppliers with NDC on PharmaCompass.

Tofacitinib GMP

Tofacitinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Tofacitinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Tofacitinib GMP manufacturer or Tofacitinib GMP API supplier for your needs.

Tofacitinib CoA

A Tofacitinib CoA (Certificate of Analysis) is a formal document that attests to Tofacitinib's compliance with Tofacitinib specifications and serves as a tool for batch-level quality control.

Tofacitinib CoA mostly includes findings from lab analyses of a specific batch. For each Tofacitinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Tofacitinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Tofacitinib EP), Tofacitinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tofacitinib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty